Innovation
Prevention is the best medicine
Prevention is about innovating to change the course of disease.
Ahead Together in genetics/genomics/vaccines/medicines/innovation
We get ahead of disease together by preventing and treating it with innovation in vaccines and specialty medicines. Our R&D approach combines our scientific focus on the immune system - with the use of advanced technologies.
We are working to deliver a new generation of differentiated, needed vaccines and medicines in four core therapeutic areas where we have the strongest expertise, and where significant patient need remains:respiratory, immunology and inflammation; oncology, HIV; and infectious diseases.
Technology powers all aspects of our R&D. We use human genetics and functional genomics, along with artificial intelligence and machine learning (AI/ML), to deeply understand the patient, human biology, and disease mechanisms. This is leading to real breakthroughs for tackling a range of conditions, such as liver disease, or transforming HIV treatment and prevention.
We believe the powerful combination of science and technology holds the key to fundamentally transforming medical discovery for the better, making the R&D process more dynamic, improving success rates and shaping how even the most challenging diseases, like neurological conditions and cancer, can be both prevented and treated.
There’s never been a time when science and technology have formed such a powerful union as they do now. We’re able to identify drug discovery targets using genomics and AI/ML in a way that is unprecedented. We’re also able to use more approaches than ever before to design new medicines and vaccines to address the root cause of disease.
Our worldwide R&D network of sites includes strategic global hubs in US, UK, Belgium and key expert facilities in Italy and Spain
We are investing in innovation in the US
Partnerships that matter
We believe the bigger the challenge the bigger the need for collaboration. We know that by working we others we can achieve more for patients than alone.
We innovate with others, because no single scientist, nor any one technology can keep us all ahead of disease. Strategic partnerships are critical to opening up new avenues of discovery and advancing the development of new potential medicines and vaccines. GSK has more than 100 active alliances in biotech and academia.
Click for more information about Partnering with GSK.
Our pipeline
As a global biopharma leader, we invest heavily in our industry-leading pipeline of potential specialty medicines and vaccines that help us to get ahead of disease together.Collaboration with US universities UCSF/UC Berkeley
The Laboratory for Genomics Research to foster innovative technologies
Therapeutic areas
The four areas of human health we focus on to get ahead of disease are: infectious diseases, HIV, respiratory/immunology, and oncology. We remain open to opportunities outside these core areas where the science aligns with our strategic approach.
Explore more about our therapeutic areas on our global website, below.
